The results of a joint study between KLT Pharmaceutical and the Academy of Military Medical Sciences, P.L.A. China show that KLT-1101 can significantly improve the survival rate of primates within 24 hours after nuclear radiation exposure and without subsequent medical support.    This product will greatly improve China's nuclear emergency drug reserve level, enhance the rescue efficiency of major nuclear accidents, increase the protection and handling capacity of public safety emergencies, and safeguard the peaceful development and utilization of atomic energy, which has great strategic significance for national defense security.